Eli Lilly and Company $LLY Shares Sold by Cidel Asset Management Inc.

Cidel Asset Management Inc. lessened its position in Eli Lilly and Company (NYSE:LLY) by 21.7% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 19,668 shares of the company’s stock after selling 5,465 shares during the quarter. Cidel Asset Management Inc.’s holdings in Eli Lilly and Company were worth $18,090,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of LLY. Richards Merrill & Peterson Inc. grew its position in Eli Lilly and Company by 2.5% in the 1st quarter. Richards Merrill & Peterson Inc. now owns 1,041 shares of the company’s stock valued at $958,000 after acquiring an additional 25 shares in the last quarter. Guyasuta Investment Advisors Inc. lifted its position in shares of Eli Lilly and Company by 2.4% during the first quarter. Guyasuta Investment Advisors Inc. now owns 2,525 shares of the company’s stock worth $2,322,000 after purchasing an additional 58 shares in the last quarter. New Covenant Trust Company N.A. lifted its position in shares of Eli Lilly and Company by 11.2% during the first quarter. New Covenant Trust Company N.A. now owns 1,169 shares of the company’s stock worth $1,075,000 after purchasing an additional 118 shares in the last quarter. Amarillo National Bank boosted its stake in shares of Eli Lilly and Company by 34.7% in the first quarter. Amarillo National Bank now owns 1,676 shares of the company’s stock valued at $1,542,000 after purchasing an additional 432 shares during the period. Finally, Presilium Private Wealth LLC boosted its stake in shares of Eli Lilly and Company by 7.2% in the first quarter. Presilium Private Wealth LLC now owns 282 shares of the company’s stock valued at $259,000 after purchasing an additional 19 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly completed its acquisition of Centessa Pharmaceuticals, strengthening its sleep-wake disorder pipeline and adding orexin-based drug development assets. Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
• Positive Sentiment: The company announced a potential $1.9 billion research collaboration with Abbisko Therapeutics, expanding its global drug-discovery efforts and pipeline optionality. Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
• Positive Sentiment: Lilly said China approval for its GLP-1 obesity/diabetes pill could come as soon as later in 2026, reinforcing expectations for another major growth driver beyond Mounjaro and Zepbound. China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
• Positive Sentiment: Management also signaled a Europe launch strategy for the obesity pill, suggesting Lilly is preparing to expand its weight-loss franchise internationally as approvals progress. Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe

Eli Lilly and Company Trading Up 0.8%

NYSE:LLY opened at $1,115.98 on Thursday. The stock has a 50-day simple moving average of $1,026.17 and a 200-day simple moving average of $1,018.81. The stock has a market cap of $1.05 trillion, a P/E ratio of 39.64, a P/E/G ratio of 1.21 and a beta of 0.53. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the business posted $3.34 EPS. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on LLY shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Wolfe Research restated an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Weiss Ratings cut Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, May 19th. Finally, Berenberg Bank increased their price objective on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,230.89.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.